Shareholders' Equity - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended					3 Months Ended	6 Months Ended	33 Months Ended
	Jan. 31, 2026	Jun. 30, 2025	Jan. 31, 2025	Dec. 31, 2024	May 31, 2024	Mar. 31, 2026	Jun. 30, 2026	Jun. 30, 2026	May 31, 2026	Aug. 31, 2024	Oct. 31, 2023
Maskbegone Agreement
Statement Line Items to SubsidiarySaleOfStockLineItems
Common stock issued (in shares)	76,383
Issuance of common shares, net of offering costs	$ 858
Obligation to issue common shares as payment under license and other agreements (in shares)							381,912
Purchase Agreement, Knopp Amendment
Statement Line Items to SubsidiarySaleOfStockLineItems
Common stock issued (in shares)		3,588,688			1,872,874
Issuance of common shares, net of offering costs		$ 51,426			$ 65,981
Merus N.V. Agreement
Statement Line Items to SubsidiarySaleOfStockLineItems
Common stock issued (in shares)			132,700
Issuance of common shares, net of offering costs			$ 4,844
FGFR3 Agreement, GeneQuantum Healthcare Co. Ltd. and Aimed Bio, Inc.
Statement Line Items to SubsidiarySaleOfStockLineItems
Obligation to issue common shares as payment under license and other agreements (in shares)				222,119
Obligation to issue common shares as payment under license and other agreements				$ 8,554
Common Shares
Statement Line Items to SubsidiarySaleOfStockLineItems
Equity distribution agreement aggregate amount							$ 350,000	$ 350,000	$ 682,000	$ 450,000	$ 150,000
Common stock issued (in shares)						17,164,940
Issuance of common shares, net of offering costs						$ 178,884
Common Shares \| Equity Distribution Agreement
Statement Line Items to SubsidiarySaleOfStockLineItems
Common stock issued (in shares)							17,164,940	21,413,528
Proceeds from sale of stock							$ 178,884	$ 325,134